Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
The industry works to develop drugs, not diseases
| The first 150 words of the full text of this article appear below. |
EDITOR
It is true that the pharmaceutical industry, with others, is
involved in sponsoring the definition of diseases, as suggested by
Moynihan et al.1 Both the pharmaceutical industry and
regulatory authorities that license new medicines need to develop
closely defined definitions so that the safety and efficacy of new
medicines can be properly measured.
More medicalisation is in fact needed, as indicated by Ebrahim and Bonaccorso and Sturchio. 2 3 The rise of guideline led care around the Western world shows that far too many serious diseases are underdiagnosed and undertreated. Failure to put evidence based medicine into practice is quite legitimately addressed by the pharmaceutical industry. Examples include the underuse of statins in the United Kingdom, the delay in the uptake of thrombolysis during the 1980s, and reliance on old psychotropic drugs when newer agents have a much more favourable profile of side effects.
Of course, disease awareness campaigns are
Read all Rapid Responses